Eli Lilly is buying a biotech startup for nearly $3 billion to expand into autoimmune diseases Aug 31, 2026 · Cris Tolomia The deal adds a pipeline targeting the antibodies behind Graves' disease, thyroid eye disease, food allergy, and other conditions Read more »
![Prediction: This Pipeline Stock's Payout Will Grow Faster Than Chevron's [or Exxon's] Over the Next 5 Years](https://media.zenfs.com/en/motleyfool.com/ce9f8ee3e848bda8f77a44da7292e1e4.jpg)
.jpg?branch=production)
